← All trials
NCT05458193
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 17, 2022
- Primary completion
- Mar 17, 2023
- Completion date
- Mar 17, 2023
- First posted
- Jul 14, 2022
- Last posted
- Nov 10, 2022
- Enrollment
- 20
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Idorsia Pharmaceuticals Ltd.Lead sponsor
- Idorsia Pharmaceuticals Ltd.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.